Trilipix, Pravafenix(choline fenofibrate)
Cholib, Pravafenix, Trilipix (choline fenofibrate) is a small molecule pharmaceutical. Choline fenofibrate was first approved as Trilipix on 2008-12-15. It has been approved in Europe to treat dyslipidemias.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Trilipix (generic drugs available since 2013-07-18, discontinued: Fenofibric acid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Choline fenofibrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRILIPIX | AbbVie | N-022224 RX | 2008-12-15 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fenofibric acid | ANDA | 2023-05-18 |
| trilipix | New Drug Application | 2020-11-04 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Choline Fenofibrate, Trilipix, Abbvie | |||
| 7259186 | 2025-01-07 | DP | |
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | 1 | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal neoplasms | D004938 | C15 | 1 | — | — | — | — | 1 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
| Lymphangioleiomyomatosis | D018192 | J84.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary hyperparathyroidism | D049950 | EFO_0008519 | E21.0 | — | — | — | — | 1 | 1 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | — | — | 1 | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CHOLINE FENOFIBRATE |
| INN | choline fenofibrate |
| Description | Cholib, Pravafenix, Trilipix (choline fenofibrate) is a small molecule pharmaceutical. Choline fenofibrate was first approved as Trilipix on 2008-12-15. It has been approved in Europe to treat dyslipidemias. |
| Classification | Small molecule |
| Drug class | antihyperlipidemics (clofibrate type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)[O-].C[N+](C)(C)CCO |
Identifiers
| PDB | — |
| CAS-ID | 856676-23-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201745 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 4BMH7IZT98 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 804 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more